Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of Oral Insulin 338 in Healthy Subjects
NCT02304627Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Insulin 338 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin 338 concentration-time curve. Started Nov 2014; status: completed.
02
Drugs
Insulin 338
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02304627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304627.